Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

NCT06310057 is registered in ClinicalTrials.gov with Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh as lead sponsor.

NCT NCT06310057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06310057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study
Lead sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2022
Completion date
March 1, 2024
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis